Pair Name	Pterostilbene, Sorafenib
Disease Info	[ICD-11: 2B72]	Gastric cancer		Investigative
Biological Phenomena	Induction-->Autophagy
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP9	hsa842
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CDK2	hsa1017
	Down-regulation	Expression	CDK4	hsa1019
	Down-regulation	Expression	CDK6	hsa1021
	Up-regulation	Expression	MAP1LC3A	hsa84557
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	SQSTM1	hsa8878
In Vitro Model	NCI-N87	Gastric tubular adenocarcinoma	Homo sapiens (Human)	CVCL_1603
	MKN45	Gastric adenocarcinoma	Homo sapiens (Human)	CVCL_0434
In Vivo Model	N87 cells (3×10⁵ cells) were suspended in 0.1 mL of PBS and inoculated subcutaneously into the right flank of five-week-old male BALB/c nude mice
Result	PET obviously enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis. The combination therapy with PET and sorafenib may serve as a novel therapeutic strategy for treating GAC and deserve further clinical trials.